Salirasib is a synthetic farnesylcysteine mimetic that inhibits ras proteins1,2 via disruption of interactions between the S-Prenyl moiety of Ras and the membrane anchorage domains3. It has been investigated in the treatment of various cancers.4,5 HCC cells pretreated with salirasib were sensitized to TRAIL-induced apoptosis.6 Salirasib has also been shown to inhibit TRPA1 (EC50 = 1.3 µM).7
* VAT and and shipping costs not included. Errors and price changes excepted
